Is there a specific reason why the big anti-viral players (GILD, GSK, etc.) haven't developed any RSV treatment (beyond the vaccines)? You would think that this would be a lucrative enough opportunity and they would have at least tried over the years. Perhaps they have, I just don't know the full back-story on attempted anti-RSV drugs over the years. Or perhaps not as lucrative an opportunity to the bigger players because a good portion get the vaccine and not as much of a need for an active treatment against RSV?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.